Q3 2022 Results

Company overview Financial review 2022 priorities Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials Cardiovascular Immunology Neuroscience Oncology iptacopan - CFB inhibitor iptacopan - CFB inhibitor References Abbreviations Other NCT04558918 APPLY-PNH (CLNP023C12302) Paroxysmal nocturnal haemoglobinuria Indication Phase Phase 3 Patients 91 Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication Percentage of participants achieving a sustained increase in hemoglobin levels of ≥ 2 g/dL in the absence of red blood cell transfusions Percentage of participants achieving sustained hemoglobin levels ≥ 12 g/dL in the absence of red blood cell transfusions Arm 1: Drug: LNP023, taken orally b.i.d. dosage supplied: 200 mg dosage form: hard gelatin capsule Route of Administration: Oral Arm 2: Drug: Eculizumab, administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose. Dosage supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion Drug: Ravulizumab, administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight. Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion Adult patients with PNH and residual anemia, despite treatment with an intravenous Anti-C5 antibody Primary 2022 Risitano AM, et al. Abstract accepted at the European Hematology Association (EHA 2021) congress (study design abstract; accepted for publication only) NCT04820530 APPOINT-PNH (CLNP023C12301) Indication Phase Paroxysmal nocturnal haemoglobinuria Phase 3 Patients 40 Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of ≥2 g/dL assessed, in the absence of red blood cell transfusions Iptacopan (LNP023), taken orally b.i.d. (dosage supplied: 200mg) PNH patients who are naive to complement inhibitor therapy, including anti- C5 antibody 2022 Peffault de Latour R, et al. Abstract accepted at the European Hematology Association (EHA 2021) congress (study design abstract; accepted for publication only) 66 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation